Congestive Heart Failure - Pipeline Analysis
“Congestive Heart Failure (CHF) Pipeline Analysis” gives comprehensive insight on the various drugs being developed for the treatment of CHF. The report covers all the drugs being developed in various development phases (Discovery to Phase 2 clinical). The pipeline focuses on disease modification and includes pharmacologic drugs, gene therapy, stem cell therapy and RNA-based therapeutics, but excludes symptom relief drugs like diuretics, acute treatments, angiotensins or thrombin inhibitors etc. The report also covers some of the hot targets in research for CHF treatments.
This report enables Pharmaceutical /Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative opportunities in the CHF Drug market. The report also provide strategic insights on medicines that are likely to have an impact on CHF treatment space and potentially alter standards of care in CHF in the foreseeable future.
Current therapies focuses only to slow down the progression of the disease as more number of molecules are symptom relieving drugs, hence it provides a tremendous opportunity for upcoming therapies specific to CHF such as gene-based, stem cell-based and miRNA-based therapies, which reverses disease course and reduce the number of cardiac events.
This report enables Pharmaceutical /Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative opportunities in the CHF Drug market. The report also provide strategic insights on medicines that are likely to have an impact on CHF treatment space and potentially alter standards of care in CHF in the foreseeable future.
Current therapies focuses only to slow down the progression of the disease as more number of molecules are symptom relieving drugs, hence it provides a tremendous opportunity for upcoming therapies specific to CHF such as gene-based, stem cell-based and miRNA-based therapies, which reverses disease course and reduce the number of cardiac events.
REPORT DESCRIPTION INTRODUCTION
Causes & Symptoms
Diagnosis
Classification
Compensatory mechanisms
Unmet needs
EPIDEMIOLOGY
Prevalence
Incidence
Hospitalizations
Re-admissions
MARKET DATA
Forecasting model
Market dynamics
Market sizing
Cost burden
PIPELINE ANALYSIS
Development stage
Modalities
Leading players
Innovative approaches
Associated targets
GENETHERAPY
Pipeline
Competitive landscape
STEMCELL THERAPY
Pipeline
Competitive landscape
RNA BASED THERAPEUTICS
mi-RNA
m-RNA
Pipeline
Competitive landscape
DRUGS (small molecules, recombinant proteins, growth factors)
Pipeline
Competitive landscape
HOT TARGETS IN RESEARCH
MAJOR PLAYERS
Company Profiles
Overview, Pipeline & Deals
REFERENCES
Causes & Symptoms
Diagnosis
Classification
Compensatory mechanisms
Unmet needs
EPIDEMIOLOGY
Prevalence
Incidence
Hospitalizations
Re-admissions
MARKET DATA
Forecasting model
Market dynamics
Market sizing
Cost burden
PIPELINE ANALYSIS
Development stage
Modalities
Leading players
Innovative approaches
Associated targets
GENETHERAPY
Pipeline
Competitive landscape
STEMCELL THERAPY
Pipeline
Competitive landscape
RNA BASED THERAPEUTICS
mi-RNA
m-RNA
Pipeline
Competitive landscape
DRUGS (small molecules, recombinant proteins, growth factors)
Pipeline
Competitive landscape
HOT TARGETS IN RESEARCH
MAJOR PLAYERS
Company Profiles
Overview, Pipeline & Deals
REFERENCES
